Rituximab offered little therapeutic benefit in Graves’ ophthalmopathy

SAN JUAN, Puerto Rico — In a randomized, double blind, placebo-controlled trial, rituximab did not effect significant clinical improvement in Graves’ ophthalmopathy and had a 50% success/failure rate in patients with the disease.“In patients with active, moderate-to-severe, progressive Graves’ ophthalmopathy, for approximately 1 year duration, rituximab does not offer a therapeutic benefit,” Marius N. Stan, MD, of the Mayo Clinic in Rochester, Minn., said. “The other side is 50% of patients improved in both groups.”

Full Story →